WORCESTER, Mass., Aug. 12, 2008 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has enrolled over 150 patients in the Company’s pivotal Phase III clinical trial of Generex Oral-lyn(tm), its flagship proprietary oral insulin spray product. Of those patients, over 100 have been dosed. There are 55 sites in the United States, Canada, Bulgaria, Russia, Poland and Ukraine actively screening and enrolling patients, including 39 clinical trial sites where patients are being dosed. Generex Oral-lyn(tm) has been shipped to all of the sites.
